Physician profile
Thomas E Gwilt
NPI 1528433158
$1,855.34
in general payments reported to CMS, 2019-2025
14 companies · $19.76 in 2025
The $19.76 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.93 · 2022: $392 · 2023: $1,203 · 2024: $165 · 2025: $19.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $843 · Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $843.00 |
| Food and Beverage | $544.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $927.81 | 2023 | Vasoview Hemopro 2 |
| Abiomed | $250.73 | 2022-2024 | Impella |
| Csl Behring | $131.49 | 2021-2023 | Kcentra |
| Genentech USA, INC. | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.62 | 2021-2022 | |
| Lilly USA, LLC | $97.60 | 2022 | |
| Ethicon US, LLC | $59.46 | 2023 | Surgicel Nu-Knit, Prolene, Stratafix |
| Baxter Healthcare | $29.07 | 2024 | Tisseel |
| Smith+Nephew, INC. | $23.30 | 2022 | |
| Acist Medical Systems, INC. | $20.76 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.76 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $16.28 | 2021 | |
| Atricure, INC. | $16.12 | 2023 | |
| Edwards Lifesciences Corporation | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gwilt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.